InfuSystem (NYSE:INFU) Stock Rating Upgraded by B. Riley

InfuSystem (NYSE:INFU - Get Free Report) was upgraded by investment analysts at B. Riley to a "strong-buy" rating in a research report issued on Thursday, May 8th,Zacks.com reports.

INFU has been the subject of several other reports. StockNews.com raised shares of InfuSystem from a "buy" rating to a "strong-buy" rating in a report on Friday, March 14th. Sidoti raised shares of InfuSystem to a "strong-buy" rating in a research report on Tuesday, March 18th.

InfuSystem Price Performance

NYSE:INFU remained flat at $5.73 during trading hours on Thursday. 2,467 shares of the company's stock were exchanged, compared to its average volume of 91,070. The company's 50-day moving average is $5.26 and its 200 day moving average is $7.13. The stock has a market cap of $120.42 million, a price-to-earnings ratio of 95.62 and a beta of 1.73. InfuSystem has a 12 month low of $4.61 and a 12 month high of $9.97. The company has a current ratio of 1.98, a quick ratio of 1.59 and a debt-to-equity ratio of 0.50.

Hedge Funds Weigh In On InfuSystem

Several large investors have recently modified their holdings of the stock. Jump Financial LLC purchased a new position in InfuSystem during the first quarter worth approximately $58,000. Hsbc Holdings PLC purchased a new position in shares of InfuSystem in the 1st quarter worth $147,000. American Century Companies Inc. bought a new stake in InfuSystem in the first quarter valued at about $256,000. Russell Investments Group Ltd. raised its position in shares of InfuSystem by 13.1% during the 1st quarter. Russell Investments Group Ltd. now owns 437,891 shares of the company's stock worth $2,356,000 after purchasing an additional 50,877 shares during the period. Finally, Nuveen LLC bought a new position in InfuSystem during the 1st quarter valued at $465,000. Institutional investors own 71.13% of the company's stock.

InfuSystem Company Profile

InfuSystem Holdings, Inc, through its subsidiaries, provides infusion pumps, and related products and services in the United States and Canada. The company operates in two segments, Patient Services and Device Solutions. It supplies electronic ambulatory infusion pumps and associated disposable supply kits to oncology, infusion, and hospital outpatient chemotherapy clinics for the treatment of various cancers, including colorectal cancer, pain management, and other disease states.